XETRA

EQS-News: Leifheit AG on track for growth again in financial year 2023

Retrieved on: 
Wednesday, April 10, 2024
Electricity, Annual, EUR, Tax, Leifheit, Growth, Supervisory board, XETRA, Household, Policy, Management, Investment, Private label, Marketing, Lithium

Free cash flow rose by EUR 3.3 million in 2023 to stand at EUR 12.1 million (2022: EUR 8.8 million).

Key Points: 
  • Free cash flow rose by EUR 3.3 million in 2023 to stand at EUR 12.1 million (2022: EUR 8.8 million).
  • We were already quite successful in that in 2023.”
    Turnover growth was driven by all core regions in 2023.
  • As in previous years, the Leifheit Group had no liabilities to banks at the end of financial year 2023.
  • The Board of Management of Leifheit AG expects slight year-on-year growth in Group turnover for financial year 2024.

EQS-News: Medios acquires Dutch market leader in pharmaceutical compounding services

Retrieved on: 
Wednesday, April 10, 2024
Tax, Consolidated, Growth, Frankfurt Stock Exchange, XETRA, FY, Patient, Pharmacy, Hospital, Acquisition, Laboratory, GMP, API, Depreciation, Fine chemical

Ceban is the Dutch market leader in compounding and has growing market positions in Belgium and Spain.

Key Points: 
  • Ceban is the Dutch market leader in compounding and has growing market positions in Belgium and Spain.
  • The purchase price for 100% of Ceban shares includes a cash component of €235.3 million and 1.7 million Medios shares.
  • The acquisition of Ceban gives Medios an outstanding position in the Dutch pharmaceutical market.
  • Ceban has a market leading position in pharmaceutical compounding in the Netherlands, a top-3 position in Belgium and a top-5 position in Spain.

EQS-News: Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Wednesday, April 10, 2024
SIRS, Schizophrenia, Clozapine, XETRA, Incidence, Patient, CNS, Peripheral nervous system, Safety, TRS, Schizophrenia International Research Society, Pharmaceutical industry

The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.

Key Points: 
  • The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.
  • As previously announced by Newron, the study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.
  • Treatment with evenamide was associated with sustained, clinically significant benefit that increased throughout the one-year course of treatment.
  • Study 008A is a four-week, randomized, double-blind and placebo-controlled study assessing the efficacy, tolerability, and safety of evenamide (30 mg bid).

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Monday, April 8, 2024
Mental Health, Research, Neurology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, SIRS, Schizophrenia, Medication, Clozapine, XETRA, Incidence, Patient, CNS, Peripheral nervous system, Safety, TRS, Schizophrenia International Research Society, Pharmaceutical industry

The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.

Key Points: 
  • The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.
  • As previously announced by Newron, the study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.
  • Treatment with evenamide was associated with sustained, clinically significant benefit that increased throughout the one-year course of treatment.
  • Study 008A is a four-week, randomized, double-blind and placebo-controlled study assessing the efficacy, tolerability, and safety of evenamide (30 mg bid).

Newron Presents 2023 Financial Results and Provides 2024 Outlook

Retrieved on: 
Tuesday, March 19, 2024
Mental Health, Research, Neurology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Psychosis, Schizophrenia, Medication, Clozapine, XETRA, Patient, CNS, Business development, Peripheral nervous system, Psychedelic literature, Safety, TRS, PANSS, EIB, Canadian International Council, Pharmaceutical industry

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.
  • Results from the first 100 patients to complete six months (30 weeks) of treatment with evenamide were reported in January, followed by results in February 2023 from the same 100-person cohort at the one-year (52 weeks) timepoint.
  • These data were further strengthened, post-period in January 2024, with the final results from study 015 reviewing all study participants after one year of treatment.
  • Patient enrollment has completed and results from this study are expected in April 2024.

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement

Retrieved on: 
Friday, March 15, 2024
Biotechnology, Banking, Professional Services, Health, General Health, Pharmaceutical, Neurology, Mental Health, Other Science, Science, Finance, EIB, Peripheral nervous system, Patient, CNS, Schizophrenia, Medication, European Investment Bank, XETRA, BofA Securities, Pharmaceutical industry

Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.

Key Points: 
  • Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.
  • The due dates for tranches four and five will stay unchanged.
  • On the amended tranches, Newron will start paying the agreed interest rates.
  • Details of the 2018 loan agreement can be found in Newron’s 2022 Annual Report which is posted on its website.

SMC Research upgrades NAGA to “Speculative BUY” with significant upside potential on back of imminent merger with Capex.com

Retrieved on: 
Wednesday, March 13, 2024
Professional Services, Apps, Applications, Technology, Cryptocurrency, Software, Finance, Fintech, SMC, Research, Research report, EUR, EGM, XETRA

The analysts of SMC Research recommend in their latest research report on The NAGA GROUP (XETRA: N4G, ISIN: DE000A161NR7), provider of the All-in-One Financial Super App, NAGA, a “Speculative BUY” (previously “HOLD”) with a Price Target of EUR 1.40, representing an upside potential of around 115% based on a share price of EUR 0.65 as of the date of the research publication.

Key Points: 
  • The analysts of SMC Research recommend in their latest research report on The NAGA GROUP (XETRA: N4G, ISIN: DE000A161NR7), provider of the All-in-One Financial Super App, NAGA, a “Speculative BUY” (previously “HOLD”) with a Price Target of EUR 1.40, representing an upside potential of around 115% based on a share price of EUR 0.65 as of the date of the research publication.
  • The Price Target implies a fully diluted market cap of EUR 318 million after the close of the contemplated merger with Capex.com The merger is expected to close in Q2 2024, subject to shareholder approval at the upcoming EGM on 12 April 2024, as well as regulatory approval.

EQS-News: Advanced Blockchain AG: Value of group’s top ten portfolio holdings increases by 45%

Retrieved on: 
Wednesday, March 13, 2024
Bitcoin, Ethereum, AB, USD, XETRA, Growth, Annual report, Lead, Blockchain, Development, Cryptocurrency

Total value of the group’s top ten holdings up to €57.5million (FY 2023: €39.65 million)

Key Points: 
  • Total value of the group’s top ten holdings up to €57.5million (FY 2023: €39.65 million)
    21 February 2024 – Advanced Blockchain AG (“AB”, Scale Frankfurt, Primary Market Düsseldorf, XETRA: ISIN DE000A0M93V6), a leading incubator, architect and investor for the blockchain industry, has significantly increased the value of its 2023 portfolio.
  • This corresponds to an increase of 45% compared to May 31, 2023, where the valuation was €39.65 million.
  • This underlines the continuous strategic efforts of Advanced Blockchain AG and its position as an innovation leader in the industry.
  • I am more convinced than ever that Advanced Blockchain will continue to benefit from the success of these companies and capitalize on this momentum.

EQS-News: Advanced Blockchain AG: Portfolio company Arweave launches new innovation and reaches a fully diluted valuation of more than $1.9 billion

Retrieved on: 
Wednesday, March 13, 2024
AB, XETRA, Ecosystem, Traction, Cryptocurrency

29th February 2024 – Arweave, a community-driven network for permanent data storage and portfolio company of Advanced Blockchain, has launched its latest innovation, the hyper parallel computer (ao: https://ao.arweave.dev/), enabling higher transaction scalability for their decentralized storage solutions.

Key Points: 
  • 29th February 2024 – Arweave, a community-driven network for permanent data storage and portfolio company of Advanced Blockchain, has launched its latest innovation, the hyper parallel computer (ao: https://ao.arweave.dev/), enabling higher transaction scalability for their decentralized storage solutions.
  • Currently, Arweave boasts a fully diluted valuation of more than $1.9 billion.
  • Arweave has reached an impressive milestone in February 2024 with more than 593 million transactions.
  • Its processing speed has also increased to an outstanding 600 transactions per second, making it one of the fastest transaction processing protocols.

EQS-News: Your Family Entertainment AG (WKN: A161N1, ISIN: DE000A161N14, abbreviation: RTV) now also listed in the m:access segment of the Munich Stock Exchange

Retrieved on: 
Wednesday, March 13, 2024
Marketing, Börse München, WKN, Family Entertainment, XETRA, Retail

Your Family Entertainment AG (WKN: A161N1, ISIN: DE000A161N14, abbreviation: RTV) now also listed in the m:access segment of the Munich Stock Exchange

Key Points: 
  • Your Family Entertainment AG (WKN: A161N1, ISIN: DE000A161N14, abbreviation: RTV) now also listed in the m:access segment of the Munich Stock Exchange
    The issuer is solely responsible for the content of this announcement.
  • Your Family Entertainment AG (WKN: A161N1, ISIN: DE000A161N14, abbreviation: RTV) now also listed in the m:access segment of the Munich Stock Exchange
    Your Family Entertainment AG, one of the leading German companies in the production and distribution of children's and family programs, is now also listed in the m:access segment (https://www.boerse-muenchen.de/maccess) of the Munich Stock Exchange.
  • Dr. Stefan Piëch, CEO of Your Family Entertainment AG: "The additional inclusion in m:access enables us to increase our reach among institutional and private investors and to demonstrate our commitment to transparency and quality.
  • The shares of Your Family Entertainment AG will be included in trading on m:access from March 11, 2024 and will continue to be traded on the existing stock exchanges in Frankfurt, Berlin, Düsseldorf, Stuttgart and XETRA.